This process is abrogated when there is a deficiency in complement and/or macrophages.12 These experimental findings were supported by human evidence, as complement activation was observed in patients with systemic amyloidosis who experienced rapid visceral amyloid clearance following administration of the anti-SAP antibody dezamizumab.15 The fact that age at disease onset in carriers of the pathogenic p.Val50Met TTR variant is influenced by functional variants of C1q lends further support to the potential role of the complement pathway in amyloid pathogenesis.16 Here, TTR is linked to amyloidosis.